Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

NCT05038020 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT05038020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 17, 2021
Completion date
April 19, 2022
Enrollment
3 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy